-
Credit Suisse analyst Kaumil Gajrawala reiterated an Outperform rating on the shares of Colgate-Palmolive Co (NYSE: CL) and lowered the price target to $85 from $88.
-
The analyst said Colgate’s shares are down 15% year-to-date owing to risks from the rising dollar and fears of global recession.
-
However, the analyst added, trends across Colgate’s categories continue to improve as the company realizes the benefits of investments, advertising is up 22% versus the pre-pandemic levels, while capex has nearly doubled.
-
Gajrawala thinks consumers in emerging markets such as Brazil and Mexico are holding up better than feared.
-
Colgate’s trends in the US tracked channels have improved sequentially, led by personal/home care.
-
Effects of destocking as Amazon.Com, Inc. (NASDAQ: AMZN) and other e-tailers close warehouses, and tightness in pet food capacity may impact Q3 shipments, though the analyst views this as temporary.
-
Gajrawala continues to forecast margins to improve sequentially as commodity inflation eases and savings from Colgate’s global productivity initiative kick in, albeit at a slower pace, given worse F/x trends.
-
He added that Colgate is showing evidence that efforts to reposition the business are starting to pay off as oral care gains market share and Hill’s growth continues.
-
Despite worse commodities and currencies, the analyst thinks the breadth of Colgate’s portfolio and under-indexing in certain categories are relative advantages.
-
Price Action: CL shares are trading higher by 0.91% at $72.80 on the last check Tuesday.
-
Photo Via Company
Latest Ratings for CL
|
Date |
Firm |
Action |
From |
To |
|---|---|---|---|---|
|
Feb 2022 |
Bernstein |
Upgrades |
Underperform |
Market Perform |
|
Jan 2022 |
Credit Suisse |
Maintains |
Outperform |
|
|
Jan 2022 |
Morgan Stanley |
Maintains |
Equal-Weight |
View More Analyst Ratings for CL
View the Latest Analyst Ratings
Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
